Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Citrullination of fibrinogen by peptidylarginine deiminase 2 impairs fibrin clot structure

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs are common and may cross-react with the murine part of IFX.
Original languageEnglish
JournalAlimentary Pharmacology and Therapeutics
Volume37
Issue number12
Pages (from-to)1172-83
Number of pages12
ISSN0269-2813
DOIs
Publication statusPublished - Jun 2013

ID: 39765484